Recently, the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), erlotinib (Tarceva®) was investigated in NSCLC after the failure of first-line or second-line chemotherapy. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.